[{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IMB-115","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA B receptor","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/ Panacea Venture"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase I","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase I","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":1.1399999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":1.1399999999999999,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Fortrea","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Acetazolamide","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Fortrea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fortrea \/ Incannex Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Fortrea \/ Incannex Healthcare"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ALKS 2680","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Centessa Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.

                          Brand Name : ORX750

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 11, 2024

                          Lead Product(s) : ORX750

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Sosei Group Corporation

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : E2086 an oral novel selective orexin-2 agonist, being investigated for narcolepsy type I in adults. Nonclinical studies have demonstrated statistically significant reductions in rates of cataplexy.

                          Brand Name : E2086

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 08, 2024

                          Lead Product(s) : E2086

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.

                          Brand Name : ORX750

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : ORX750

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Centessa Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist, which is being evaluated for the treatment of narcolepsy type 2 & idiopathic hypersomnia.

                          Brand Name : ALKS 2680

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 09, 2024

                          Lead Product(s) : ALKS 2680

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obst...

                          Brand Name : IHL-42X

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 18, 2023

                          Lead Product(s) : Acetazolamide,Tetrahydrocannabinol

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Incannex Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : IHL-42X (dronabinol) is a fixed-dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea (‘OSA’) in adults.

                          Brand Name : IHL-42X

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 17, 2022

                          Lead Product(s) : Tetrahydrocannabinol,Acetazolamide

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The data suggest that KP1077 (serdexmethylphenidate) produces a smoother, more gradual release of d-MPH that may avoid the adverse events associated with large and rapid exposure fluctuations that may be experienced with other stimulant-based therapies.

                          Brand Name : KP1077

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 05, 2022

                          Lead Product(s) : Serdexmethylphenidate

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...

                          Brand Name : JZP441

                          Molecule Type : Small molecule

                          Upfront Cash : $50.0 million

                          May 04, 2022

                          Lead Product(s) : DSP-0187

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Jazz Pharmaceuticals

                          Deal Size : $1,140.0 million

                          Deal Type : Licensing Agreement